187 related articles for article (PubMed ID: 33129304)
1. Health-related quality of life in patients with inoperable malignant bowel obstruction: secondary outcome from a double-blind, parallel, placebo-controlled randomised trial of octreotide.
McCaffrey N; Asser T; Fazekas B; Muircroft W; Agar M; Clark K; Eckermann S; Lee J; Joshi R; Allcroft P; Sheehan C; Currow DC
BMC Cancer; 2020 Oct; 20(1):1050. PubMed ID: 33129304
[TBL] [Abstract][Full Text] [Related]
2. Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction.
Currow DC; Quinn S; Agar M; Fazekas B; Hardy J; McCaffrey N; Eckermann S; Abernethy AP; Clark K
J Pain Symptom Manage; 2015 May; 49(5):814-21. PubMed ID: 25462210
[TBL] [Abstract][Full Text] [Related]
3. Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double- blind, controlled clinical trial.
Mystakidou K; Tsilika E; Kalaidopoulou O; Chondros K; Georgaki S; Papadimitriou L
Anticancer Res; 2002; 22(2B):1187-92. PubMed ID: 12168923
[TBL] [Abstract][Full Text] [Related]
4. Assessing quality of life in palliative care settings: head-to-head comparison of four patient-reported outcome measures (EORTC QLQ-C15-PAL, FACT-Pal, FACT-Pal-14, FACT-G7).
King MT; Agar M; Currow DC; Hardy J; Fazekas B; McCaffrey N
Support Care Cancer; 2020 Jan; 28(1):141-153. PubMed ID: 30993452
[TBL] [Abstract][Full Text] [Related]
5. Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction.
Hisanaga T; Shinjo T; Morita T; Nakajima N; Ikenaga M; Tanimizu M; Kizawa Y; Maeno T; Shima Y; Hyodo I
Jpn J Clin Oncol; 2010 Aug; 40(8):739-45. PubMed ID: 20410056
[TBL] [Abstract][Full Text] [Related]
6. Clinician-reported changes in octreotide prescribing for malignant bowel obstruction as a result of an adequately powered phase III study: A transnational, online survey.
Campbell R; McCaffrey N; Brown L; Agar MR; Clark K; Currow DC
Palliat Med; 2018 Sep; 32(8):1363-1368. PubMed ID: 29856291
[TBL] [Abstract][Full Text] [Related]
7. Health-Related Quality of Life for Long-Acting Octreotide versus Placebo in Patients with Metastatic Midgut Neuroendocrine Tumors in the Phase 3 PROMID Trial.
Rinke A; Neary MP; Eriksson J; Hunger M; Doan T; Karli D; Arnold R
Neuroendocrinology; 2019; 109(2):141-151. PubMed ID: 30852564
[TBL] [Abstract][Full Text] [Related]
8. Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial.
Coens C; Suciu S; Chiarion-Sileni V; Grob JJ; Dummer R; Wolchok JD; Schmidt H; Hamid O; Robert C; Ascierto PA; Richards JM; Lebbé C; Ferraresi V; Smylie M; Weber JS; Maio M; Bottomley A; Kotapati S; de Pril V; Testori A; Eggermont AMM
Lancet Oncol; 2017 Mar; 18(3):393-403. PubMed ID: 28162999
[TBL] [Abstract][Full Text] [Related]
9. Palliation of malignant intestinal obstruction using octreotide.
Khoo D; Hall E; Motson R; Riley J; Denman K; Waxman J
Eur J Cancer; 1994; 30A(1):28-30. PubMed ID: 7511400
[TBL] [Abstract][Full Text] [Related]
10. SALTO: a randomized, multicenter study assessing octreotide LAR in inoperable bowel obstruction.
Laval G; Rousselot H; Toussaint-Martel S; Mayer F; Terrebonne E; François E; Brixi H; Nguyen T; Bourdeix I; Bisot-Locard S; Zelek L;
Bull Cancer; 2012 Feb; 99(2):E1-9. PubMed ID: 22265994
[TBL] [Abstract][Full Text] [Related]
11. Octreotide in the management of bowel obstruction in terminal ovarian cancer.
Mangili G; Franchi M; Mariani A; Zanaboni F; Rabaiotti E; Frigerio L; Bolis PF; Ferrari A
Gynecol Oncol; 1996 Jun; 61(3):345-8. PubMed ID: 8641613
[TBL] [Abstract][Full Text] [Related]
12. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction.
Mercadante S; Ripamonti C; Casuccio A; Zecca E; Groff L
Support Care Cancer; 2000 May; 8(3):188-91. PubMed ID: 10789958
[TBL] [Abstract][Full Text] [Related]
13. Octreotide prescribing patterns in the palliation of symptomatic inoperable malignant bowel obstruction patients at a single US academic hospital.
Hwang M; Pirrello R; Pu M; Messer K; Roeland E
Support Care Cancer; 2013 Oct; 21(10):2817-24. PubMed ID: 23732621
[TBL] [Abstract][Full Text] [Related]
14. A prospective study on the efficacy of octreotide in the management of malignant bowel obstruction in gynecologic cancer.
Watari H; Hosaka M; Wakui Y; Nomura E; Hareyama H; Tanuma F; Hattori R; Azuma M; Kato H; Takeda N; Ariga S; Sakuragi N
Int J Gynecol Cancer; 2012 May; 22(4):692-6. PubMed ID: 22343971
[TBL] [Abstract][Full Text] [Related]
15. The palliative effects of octreotide in malignant disease.
Dean A; Bridge D; Lickiss JN
Ann Acad Med Singap; 1994 Mar; 23(2):212-5. PubMed ID: 7521613
[TBL] [Abstract][Full Text] [Related]
16. Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer.
Peng X; Wang P; Li S; Zhang G; Hu S
World J Surg Oncol; 2015 Feb; 13():50. PubMed ID: 25889313
[TBL] [Abstract][Full Text] [Related]
17. Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study.
Barbare JC; Bouché O; Bonnetain F; Dahan L; Lombard-Bohas C; Faroux R; Raoul JL; Cattan S; Lemoine A; Blanc JF; Bronowicki JP; Zarski JP; Cazorla S; Gargot D; Thevenot T; Diaz E; Bastie A; Aparicio T; Bedenne L
Eur J Cancer; 2009 Jul; 45(10):1788-97. PubMed ID: 19303768
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of palliative treatment using octreotide for inoperable malignant bowel obstruction caused by advanced urological cancer.
Kubota H; Taguchi K; Kobayashi D; Naruyama H; Hirose M; Fukuta K; Kubota Y; Yasui T; Yamada Y; Kohri K
Asian Pac J Cancer Prev; 2013; 14(12):7107-10. PubMed ID: 24460259
[TBL] [Abstract][Full Text] [Related]
19. Octreotide for malignant bowel obstruction: twenty years after.
Mercadante S; Porzio G
Crit Rev Oncol Hematol; 2012 Sep; 83(3):388-92. PubMed ID: 22277783
[TBL] [Abstract][Full Text] [Related]
20. Practice Patterns of Medications for Patients With Malignant Bowel Obstruction Using a Nationwide Claims Database and the Association Between Treatment Outcomes and Concomitant Use of H
Minoura T; Takeuchi M; Morita T; Kawakami K
J Pain Symptom Manage; 2018 Feb; 55(2):413-419.e2. PubMed ID: 29122616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
